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Obese adolescents have high concentrations of saturated fatty acids and low omega-3 long-chain polyunsaturated fatty acids
(LCUFAs) in plasma phospholipids. We aimed to investigate eﬀects of omega-3 LCPUFA supplementation to obese adolescents
on skeletal muscle lipids and glucose and insulin homeostasis. Twenty-ﬁve obese adolescents (14–17 years old, 14 females)
completed a randomized double-blind crossover study supplying capsules containing either 1.2g omega-3 LCPUFAs or placebo,
for 3 months each with a six-week washout period. Fasting blood glucose, insulin, leptin, adiponectin, and lipids were measured.
Intravenousglucosetolerancetest(IVGTT)andeuglycemic-hyperinsulinemicclampwereperformed,andskeletalmusclebiopsies
were obtained at the end of each period. The concentrations of EPA, DHA, and total omega-3 PUFA in muscle phospholipids
increased in both sexes. In the females, omega-3 LCPUFA supplementation improved glucose tolerance by 39% (P = 0.04) and
restored insulin concentration by 34% (P = 0.02) during IVGTT. Insulin sensitivity improved 17% (P = 0.07). In males, none
of these parameters was inﬂuenced by omega-3 supplementation. Thus, three months of supplementation of omega-3 LCPUFA
improved glucose and insulin homeostasis in obese girls without inﬂuencing body weight.
1.Introduction
The prevalence of childhood obesity continues to increase
[1], and obesity-related adverse conditions, such as high
blood pressure, increased left ventricular mass, insulin
resistance, and type 2 diabetes, are now being seen in
children with increasing frequency [2, 3]. The association
of obesity with type 2 diabetes has been recognized for
decades, and the major basis for this link is the characteristic
association of obesity to insulin resistance. Insulin resistance
plays an important role in the pathogenesis of the metabolic
syndrome, and yet, the mechanisms remain enigmatic.
It has been shown recently that obese children, with their
prevailingriskproﬁle,havelowerserumlevelsoftheessential
fatty acids (FAs) of the omega-3 series than age-matched
lean controls [4, 5]. Risk factors for cardiovascular disease
have mainly been referred to saturated FA and trans FA, but
diabetes and obesity have also been suggested to more relate
to decreased omega-3 FA than to the total amount of dietary
fat [6–8]. Earlier studies have demonstrated that increasing
the omega-3 LCPUFA concentrations, using Mediterranean
inspired diet or omega-3 supplementation, lowered plasma
triacylglycerols, inﬂammatory markers, platelets, and white
blood cells in both healthy and obese individuals [9–11].
Omega-3 LCPUFA supplementation has also been shown to
improve insulin sensitivity in overweight adults [12].
The skeletal muscle, liver, and adipose tissue are known
to play a pivotal role in the development of insulin resistance
[13, 14]. Insulin sensitivity has been shown to be related to
the FA composition of muscle phospholipids [15]. Hence,2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
we hypothesized that increasing the omega-3 LCPUFA levels
in the skeletal muscle might have beneﬁcial inﬂuence on
metabolism and cardiovascular risk in obese adolescents.
The purpose of the present study was to investigate the
eﬀect of omega-3 LCPUFA supplementation on glucose and
insulin metabolism in obese adolescents more thoroughly.
Given that girls with obesity are at greater risk for impaired
insulin sensitivity than boys [16], analyses of data were
separated by gender. In order to focus on the eﬀect of the
supplementation, no intervention was made for physical
activity or diet.
2.SubjectsandMethods
2.1. Study Subjects. One-hundred and eight obese adoles-
cents (14–17 years), referred to our outpatient clinic, were
invited to enroll in the study. Only 47 participated in an
information meeting, and 31 of these agreed to participate.
One subject was excluded due to smoking, one moved
abroad, three withdrawn during the study, and one was
excluded due to poor compliance. Thus, 14 females (aged
15.6 ± 0.9, BMI z-score 2.1 ± 0.2) and 11 males (aged
15.7 ± 1.0, BMI z-score 2.4 ± 0.4) completed the study. For
anthropometry, see Table 1. Information and written proto-
cols, approved by the Ethics Committee of the Sahlgrenska
Academy at the University of Gothenburg, were presented,
and written consent was obtained from the adolescents
and their parents. Obesity was deﬁned by the International
Obesity Task Force criteria [17]. No adolescent reported
chronic disease or regular use of medications. All were at
pubertal Tanner stage > 4 regarding both gonad size and
pubic hair. All females were after menarche.
2.2.StudyDesign. Thestudywasperformedinarandomized
double-blind, crossover design with a six-week washout per-
iod. A random number generator performed the random-
ization. Each adolescent was randomized to a daily intake
of 10 capsules (EyeQ, Equazen, Wigan, UK), providing
1.2g omega-3 LCPUFA (930mg eicosapentaenoic acid (EPA,
20:5n-3), 290mg docosahexaenoic acid (DHA, 22:6n-3),
100mg γ-linolenic acid (GLA, 18:3n-6), and 18mg vitamin
E daily or placebo capsules containing medium chain
triglycerides (MCT); in total the same amount of fats was
g i v e nw i t hb o t ht r e a t m e n t s .T h es u b j e c t sw e r ei n s t r u c t e dt o
take the capsules once a day before breakfast. Physical exam-
ination, blood samples, and anthropometric measurements
were taken before the supplementation and after each 3-
month period. Serum phospholipid FA analyses were per-
formed at the end of the washout period to verify that
the omega-3 LCPUFA concentrations were back to baseline
levels.
At the end of each period, muscle biopsies were ob-
tained, and intravenous glucose tolerance test (IVGTT) and
hyperinsulinemic-euglycemic clamp were performed. Re-
sults of investigation of vascular function and inﬂamma-
tion have previously been reported [18].
The adherence to the supplementation was monitored by
monthly contacts. Leftover capsules and records of capsule
intake were presented to one of the investigators, and one
subject with compliance below 75% was excluded. For
control of the diet, subjects completed a semiquantitative
food-frequency questionnaire before each period, which re-
vealed no diﬀerence in dietary intake pattern. For the phys-
ical activity, the subjects were asked to keep their habits
duringthestudy,andaccordingtotheregularcheckupsdone
during the study periods, there was no change in the physical
activity.
2.3. Intravenous Glucose Tolerance Test (IVGTT). After an
overnight fast, two catheters were inserted, one into the left
antecubital vein for infusions of glucose, and another one
into an ipsilateral heated dorsal hand vein for withdrawal
of arterialized venous blood. After baseline blood collection,
300mg glucose/kg body weight (30% glucose solution) was
given within two minutes. Blood samples were drawn every
second minute to 10 minutes, thereafter every 5 minutes
to 30 minutes and then every 10 minutes to 120 minutes
after the glucose infusion. Plasma glucose was analyzed with
a glucose analyzer (HemoCue Glucose 201 DM Analyzer,
HemoCue AB, Sweden), and serum insulin was analyzed by
Enzyme-Linked Immunosorbent Assay (ELISA, Mercodia,
Uppsala, Sweden). Analysis of glucose and insulin response
to IVGTT was performed according to Kahn et al. [19]. The
magnitude of insulin response to glucose was quantiﬁed as
the incremental area under the curve (ΔAUC) and divided
intodiﬀerenttimeperiods,0–10minutesand60–80minutes,
reﬂecting the ﬁrst phase insulin secretion and the restoration
of insulin concentration, respectively. Glucose disappearance
constant (Kg) was calculated as the slope of the logarithm of
glucose values between 10 and 30 minutes after the glucose
infusion.
2.4. Euglycemic Hyperinsulinemic Clamp. Thirty minutes
after the IVGTT, a euglycemic hyperinsulinemic clamp was
carried out for evaluating insulin sensitivity. This design has
been previously validated [20]. Human insulin (Actrapid,
Novo Nordisk, Copenhagen, Denmark) was infused as a
priming dose, followed by continuous infusion (80mU/m2
body surface/min) for 120 minutes. Glucose infusion was
started simultaneously and the infusion rate adjusted to
clamp the blood glucose at 5.0mmol/L, assessed at 5-minute
intervals using the glucose analyzer. The glucose infusion
rate during the last 60 minutes was a measure of the
subject’s insulin sensitivity expressed as glucose disposal rate
(GDR) (mg/kg body weight/min). The GDR (M-value) was
calculated as the mean value of the glucose infused for each
20-minute interval during the last 60 minutes of the clamp.
The insulin sensitivity index (ISI) was calculated by dividing
the M-value by the steady-state insulin concentration during
the last 60 minutes of the clamp (mg glucose/kg body
weight/min/insulin (mU/L)) [20].
2.5. Blood Sample Analysis. Fasting blood samples were tak-
en before and after the supplementations. Blood glucose,
total cholesterol, HDL-cholesterol, LDL-cholesterol, and
triacylglycerols were analyzed by enzymatic methods (RocheJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Diagnostics, Mannheim, Germany) according to routine
(Sahlgrenska University Hospital, G¨ oteborg). Fasting serum
insulin was analysed with ELISA. The intra-assay coeﬃcient
of variation for insulin was 3.3%. Plasma leptin was analyzed
by ELISA from Mercodia (Uppsala, Sweden) and high-
molecular weight-adiponectin (HMW-Adiponectin) was
analyzed by ELISA from Linco (St. Charles, Missouri, USA).
Coeﬃcients of variation within assays were 3.7% for leptin
and 16% for HMW-Adiponectin. Some of the results have
previously been reported for the whole study sample but are
here given by gender [18].
2.6. Biopsies. After intra- and subcutaneous administration
of local anaesthesia (Mepivacain, 10mg/mL, Carbocain, As-
trazeneca, Sweden), muscle biopsies were obtained from
M. vastus lateralis with a Bergmann needle after each per-
iod from 18 (11 female) of the subjects. Biopsies were im-
mediatelyfrozeninliquidnitrogenandstoredat −70◦Cuntil
analysis.
2.7. Fatty Acid Analysis. Fatty acid analyses were performed
in serum and muscle biopsies. After lipid extraction, serum
phospholipidswerefractionatedonasingleSEP-PAKamino-
propyl cartridge (Waters Corp., Beverly, MA, USA), trans-
methylated, and separated by capillary GLC in a Hewlett-
Packard 6890 gas chromatograph (Palo Alto, CA, USA) as
previously reported [21]. The biopsies were homogenized
with a Polytron PT 1200 homogenizer (Kinematica AG)
in 400μL of water. After the addition of isopropanol, the
homogenate was sonicated and chloroform was added,
together with 100μg n-oleoyl-ethanolamine as internal stan-
dard (Sigma-Aldrich, Sweden AB, Stockholm) and 2,6-di-
tert-butyl-4-methylphenol (BHT) 0.1mg/mL chloroform.
The homogenate was incubated for 1 hour and then
centrifuged at 2000g for 10 minutes. After extraction with
chloroform-methanol solution (2:1), the extract was ﬁltered
(Acrodisc PTFE, 0.45-μm ﬁltering capacity; Waters Corpora-
tion, Milford, MA). The ﬁltrate was evaporated and resolved
in 100μL hexane: 2-propanol: HAc: 3-ethylamine solution
(50:50:1.5:0.1). The sample was injected in a high perfor-
mance liquid chromatograph with a LiChrospher 100DIOL
column (dimension = 250 × 4mm; ﬁlm thickness = 5μm)
at 55◦C with split ﬂow to an evaporative light-scattering
detector and fraction collection. Hexane: 2-propanol: HAc:
3-ethylamine (82:17:1.5:0.1) and 2-propanol: H2O: HAc:
3-ethylamine (84:15:1.5:0.1) solutions were used as binary
gradients.Theﬂowwas0.8mL/min.Fractionswerecollected
for phosphatidylcholine, phosphatidylethanolamine, phos-
phatidylserine, phosphatidylinositol, diphosphoglycerides,
phosphoglycerides, and sphingomyelin. The two latter were
small, and those and the neutral lipid fraction were not
further analysed, but diﬀerent phospholipid fractions were
esteriﬁed by incubation for 4 hours at a temperature of
80◦C with methanol HCl-3N and 2μg heneicosanoic acid
methyl ester added as an internal standard. The methyl esters
were extracted with hexane, washed with Millipore water
and dried over MgSO4 and analysed on GLC as previously
described [21].
2.8. Statistical Analysis. Statistical analyses were performed
with the SPSS 15.0. Paired samples t-test was used where
applicable. Variables that were not normally distributed were
analyzed by Wilcoxon signed-ranks test. All results are ex-
pressed as means ± SD or median and range where applica-
ble. GraphPad Prism 4.03 was used for all curve analysis of
glucose and insulin response during IVGTT, speciﬁcally area
undercurveandslope.AP<0.05wasconsideredstatistically
signiﬁcant.
3. Results
The baseline parameters of the omega-3 LCPUFA supple-
mentation periods did not diﬀer from those of the placebo
periods (Table 1). No signiﬁcant diﬀerences between the
omega-3 LCPUFA and the placebo supplementations were
found regarding body weight, BMI, or any blood parameters
(Table 1). The omega-3 LCPUFA supplementation signif-
icantly increased the omega-3 LCPUFA concentrations in
phospholipids of serum (Table 1,[ 18]) and skeletal muscle
(Table 2), as compared with placebo supplementation.
3.1. Glucose Tolerance and Insulin Sensitivity. In females,
the glucose tolerance (Kg) was signiﬁcantly improved after
omega-3 LCPUFA supplementation (omega-3: −0.0257 ±
0.0119;control: −0.0185±0.0093, P<0.05,Figure 1).Inline
with this, ISI obtained from euglycemic-hyperinsulinemic
clamp tended to be increased (omega-3: 0.047 ± 0.016;
control: 0.039 ± 0.015mg·kg−1·min−1·(mU/L)−1, P =
0.07). The restoration of insulin concentration during
IVGTT was also improved (ΔAUC60−80 min , omega-3: 616 ±
425 and placebo: 937 ± 496 mU·L−1·min−1, P = 0.02,
Figure 1). The omega-3 LCPUFA supplementation did not
change the ﬁrst-phase insulin secretion during IVGTT
(ΔAUC0−10 min) (omega-3: 1098 ± 559; placebo: 1174 ±
726 mU·L−1·min−1) or GDR obtained from euglycemic-
hyperinsulinemic clamp (omega-3: 6.8 ± 3.7, placebo: 7.4 ±
3.2mg/kg body weight/min).
In males, the omega-3 LCPUFA supplementation did not
changetheKg (omega-3: −0.022±0.0103; placebo: −0.025±
0.0106,Figure 1),theISI(omga-3:0.046±0.034andplacebo:
0.051±0.041mg·kg−1·min−1·(mU/L)−1),theGDR(omega-
3: 6.8 ± 3.7; placebo: 7.4 ± 3.2mg/kg body weight/min),
the restoration of insulin concentration (ΔAUC60−−80 min,
omega-3: 1390 ± 1026 and placebo: 1002 ± 1092, Figure 1),
ortheΔAUC0−−10 min (omega-3:1076 ±400;control: 1050±
552 mU·L−1·min−1).
3.2. Muscle Fatty Acid Composition. In skeletal muscle phos-
pholipids (Table 2), the percentage of total omega-3PUFAs
was 47% and 45% higher after omega-3 LCPUFA supple-
mentation than after placebo in females and males, res-
pectively. The percentage of total omega-6PUFAs and lino-
leic acid (LA, 18:2n-6) decreased in both females and males,
while arachidonic acid (AA, 20:4n-6) decreased only in
males (Table 2). The concentration of EPA was increased
more than 115% after omega-3 LCPUFA supplementation
in both females and males. Signiﬁcant increase in DHA4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Anthropometric and biochemical measures at baseline and after 3-month treatment with n-3PUFAs or placebo in 11 male and 14
female obese subjects.
Male Female
Omega 3 Control P value Omega 3 Control P
value
Baseline
After
3-month
treatment
Baseline
After
3-month
treatment
Baseline
After
3-month
treatment
Baseline
After
3-month
treatment
Height (m) 1.75 ±0.06 1.77 ±0.06 1.76 ±0.06 1.77 ±0.06 ns 1.65 ±0.06 1.66 ±0.06 1.66 ±0.06 1.67 ±0.06 0.002
Weight (kg) 108.8±19.4 111.7±20.11 111.0±19.7 111.7±19.3n s9 0 .9 ±11.19 1 .8 ±12.09 1 .6 ±12.49 3 .6 ±13.0n s
BMI (kg/m2) 35.2 ±5.13 5 .7 ±5.43 5 .7 ±5.13 5 .5 ±5.0n s3 3 .1 ±2.73 3 .1 ±3.23 3 .1 ±3.43 3 .7 ±3.5n s
Waist (cm) 113.8±14.1 111.4 ±13.3 116.8±13.0 111.6±12.5 ns 106.6 ±9.19 8 .4 ±9.1 104.5±11.89 7 .6 ±9.1n s
Hip (cm) 116.8±12.0 116.0 ±12.3 120.5 ±9.1 118.4±10.5 ns 116.3 ±7.0 112.5 ±6.5 116.5 ±5.5 113.0 ±6.1n s
Serum phospholipid
w-3 concentration
(mol%)
4.9 ±1.18 .0 ±1.55 .3 ±1.25 .1 ±1.1 <0.0001 5.9 ±1.51 0 .0 ±2.56 .4 ±1.36 .4 ±2.6 0.001
Total cholesterol
(mmol/L) 4.0 ±0.63 .9 ±0.54 .2 ±0.73 .8 ±0.7n s4 .3 ±0.74 .1 ±0.74 .2 ±0.73 .9 ±0.7n s
Triacylglycerol
(mmol/L) 1.5 ±0.61 .1 ±0.41 .3 ±0.51 .1 ±0.5n s1 .2 ±0.50 .9 ±0.41 .2 ±0.61 .1 ±0.6n s
HDL cholesterol
(mmol/L) 1.2 ±0.21 .2 ±0.21 .2 ±0.21 .2 ±0.2n s1 .3 ±0.31 .3 ±0.21 .3 ±0.21 .3 ±0.2n s
LDL cholesterol
(mmol/L) 2.2 ±0.62 .2 ±0.52 .4 ±0.62 .1 ±0.60 . 0 72 .4 ±0.62 .2 ±0.62 .3 ±0.62 .1 ±0.7n s
Glucose (mmol/L) 4.8 ±0.45 .2 ±0.44 .9 ±0.55 .0 ±0.3n s4 .4 ±0.34 .8 ±0.34 .6 ±0.44 .7 ±0.4n s
Insulin (μU/L) 13.0 ±6.71 4 .4 ±8.41 4 .5 ±8.91 0 .0 ±3.8n s1 0 .6 ±4.61 2 .9 ±5.71 1 .6 ±4.21 3 .9 ±11.1n s
HMW-adiponectin
(mg/mL) 3.2 ±1.63 .0 ±2.04 .0 ±2.43 .9 ±2.6n s5 .5 ±3.85 .2 ±4.55 .4 ±2.74 .3 ±2.7n s
Leptin (ng/mL) 27 ± 19 26 ± 18 29 ± 20 29 ± 22 ns 53 ± 18 57 ± 16 53 ± 18 63 ± 23 ns
Data are presented as mean ± SD. Statistical signiﬁcance was calculated as the diﬀerence between the starting value and that at the end of the treatment period
for each treatmentarm,andthesediﬀerences were tested by paired t testor Wilcoxon signed-rankstestfor nonnormallydistributedvariables.For all variables,
there were no signiﬁcant diﬀerences between the means at the beginning of the 2 treatment periods. BMI, body mass index; HMW, high molecular weight.
was also seen. Accordingly, the omega-6/omega-3 ratio was
lower with omega-3 LCPUFA supplementation than with
placebo. Total or individual SFA and MUFA were not chan-
ged. Similar pattern of FA changes were found in phos-
phatidylethanolamine and phosphatidylcholine, whereas in
phosphatidylserine omega-6 FA was lower with the omega-3
supplementation. The FA composition of phosphatidylinos-
itol and diphosphoglycerides (cardiolipin) remained largely
unchanged.
The triacylglycerols in muscles were lower after omega-3
supplementation than after placebo (females omega-3: 25.5
(9.5–116.0), placebo: 38.7 (7.8–86.1) mg/g wet weight and
males omega-3: 39.4 (11.7–57.3) and placebo: 46.2 (26.6–
140.0) mg/g wet weight). However, the diﬀerences were not
signiﬁcant.
The placebo capsules did not cause any signiﬁcant chan-
ges in serum concentrations of glucose, insulin and triacyl-
glycerols (Table 1), suggesting that the MCT did not aﬀect
the insulin-glucose metabolism and fatty acid oxidation.
The absence of any inﬂuence on body weight also indicated
that the energy supply was negligible. Carryover eﬀects of
receiving omega-3 LCPUFA or MCT capsules ﬁrst were
checked for the analysed variables, and no such eﬀects were
found.
4. Discussion
This study shows that omega-3 LCPUFA supplementation in
a high physiological dose of 1.2g/day for 3 months improved
glucose and insulin homeostasis in obese girls without
concomitant weight reduction. This eﬀect was not found
in the obese boys. The omega-3 LCPUFA supplementation
also increased incorporation of omega-3 LCPUFAs into the
skeletal muscle phospholipids in both gender, as reﬂected
in the increased levels of omega-3 LCPUFAs in this tissue.
The triacylglycerides in muscle were decreased, although not
reaching signiﬁcance.
Glucose tolerance, determined as glucose disappearance
constant (Kg) during IVGTT, is inﬂuenced by insulin
secretion from the pancreatic β-cells and insulin sensitivity
in the liver and peripheral tissues [22]. The increased glucose
tolerance after the omega-3 LCPUFA supplementation in
females was probably due to an improvement in insulin sen-
sitivity rather than insulin secretion, since the ﬁrst-phase of
insulin secretion was not changed by the omega-3 LCPUFA
supplementation. In line with this, we found a moderate
increase of insulin sensitivity, determined as ISI by the
euglycemic-hyperinsulinemic clamp. Thus, our data indicate
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Table 2: Fatty acid compositions of total muscle phospholipids and of major glycerophospholipids, phosphatidylcholine (PC), phosphati-
dylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and cardiolipin (DPG) in 12 females and 7 males after 3-months
treatment with omega-3 LCPUFAs or placebo, expressed as molar percentage of total FA.
Female (n = 12)
P value
Male (n = 7)
P value
ω-3 Control ω-3 Control
ΣSFA 32.6 ±1.53 3 .2 ±1.5n s 3 1 .6 ±0.43 2 .0 ±0.6n s
ΣMUFA 6.8 ±1.07 .1 ±0.9n s 6 .0 ±0.86 .4 ±1.0n s
ΣPUFA 60.6 ±1.85 9 .7 ±2.0n s 6 2 .3 ±1.06 1 .6 ±1.4n s
Σω-6 52.8 ±2.45 4 .4 ±2.5 0.019 53.8 ±1.85 6 .0 ±1.5 0.013
18:2ω-6 (LA) 38.7 ±2.44 0 .1 ±2.2 0.017 38.9 ±1.84 0 .3 ±1.9 0.047
20:4ω-6 (AA) 12.1 ±1.21 2 .1 ±1.3n s 1 2 .7 ±1.81 3 .5 ±1.8 0.027
Σω-3 7.5 ±0.95 .1 ±1.1 <0.0001 7.7 ±1.85 .3 ±1.7 <0.0001
18:3ω-3 (ALA) 0.4 ±0.10 .4 ±0.1n s 0 .3 ±0.00 .4 ±0.1n s
20:5ω-3 (EPA) 2.5 ±0.51 .1 ±0.4 <0.0001 2.8 ±0.61 .3 ±0.6 <0.0001
22:6ω-3 (DHA) 2.8 ±0.42 .1 ±0.6 <0.0001 2.8 ±1.02 .1 ±0.9 0.001
ω-6/ω-3 ratio 7.1 ±1.21 1 .3 ±2.8 <0.0001 7.3 ±2.01 1 .7 ±3.9 0.002
PC
Σω-6 42.5 ±4.94 5 .2 ±1.6 0.026 45.0 ±0.74 5 .1 ±1.6n s
18:2ω-6 (LA) 39.0 ±4.84 1 .5 ±1.7 0.091 41.0 ±1.24 1 .2 ±2.0n s
20:4ω-6 (AA) 2.4 ±0.22 .5 ±0.3n s 2 .8 ±0.52 .8 ±0.4n s
Σω-3 2.4 ±0.61 .6 ±0.5 0.003 2.4 ±0.51 .7 ±0.6 0.018
18:3ω-3 (ALA) 0.4 ±0.20 .4 ±0.2n s 0 .4 ±0.00 .4 ±0.1n s
20:5ω-3 (EPA) 0.8 ±0.20 .4 ±0.2 0.003 0.9 ±0.30 .4 ±0.2 0.018
22:6ω-3 (DHA) 0.6 ±0.30 .4 ±0.1 0.012 0.6 ±0.20 .4 ±0.2 0.089
ω-6/ω-3 ratio 19.0 ±5.03 1 .0 ±9.3 0.003 20.0 ±5.23 0 .0 ±11.0 0.018
PE
Σω-6 37.9 ±4.24 3 .7 ±2.4 0.005 39.0 ±4.04 3 .4 ±4.7 0.028
18:2ω-6 (LA) 10.1 ±1.91 1 .4 ±1.4 0.037 9.8 ±2.61 0 .4 ±2.8 0.075
20:4ω-6 (AA) 27.4 ±3.43 1 .8 ±3.3 0.005 28.6 ±3.13 2 .4 ±4.4 0.046
Σω-3 13.3 ±3.88 .9 ±2.3 0.009 12.8 ±3.97 .7 ±3.1 0.028
18:3ω-3 (ALA) 0.06 ±0.05 0.10 ±0.05 0.059 0.08 ±0.06 0.11 ±0.09 ns
20:5ω-3 (EPA) 4.6 ±1.32 .3 ±0.7 0.005 4.8 ±0.82 .3 ±0.9 0.028
22:6ω-3 (DHA) 7.5 ±2.25 .5 ±1.5 0.022 6.7 ±3.14 .3 ±2.2 0.028
ω-6/ω-3 ratio 3.1 ±0.95 .3 ±1.6 0.005 3.4 ±1.36 .6 ±2.9 0.028
PS
Σω-6 13.8 ±3.11 7 .3 ±2.5 0.008 14.1 ±4.41 9 .0 ±6.7 0.028
18:2ω-6 (LA) 7.3 ±2.09 .17 ±1.8 0.021 7.2 ±4.21 0 .9 ±6.3 0.028
20:4ω-6 (AA) 4.1 ±1.15 .7 ±1.4 0.021 4.1 ±1.15 .7 ±2.4 0.018
Σω-3 18.5 ±3.11 6 .4 ±4.0n s 2 0 .1 ±6.91 9 .1 ±6.4n s
18:3ω-3 (ALA) 0.01 ±0.05 0.04 ±0.12 ns 0.02 ±0.06 0.21 ±0.42 ns
20:5ω-3 (EPA) 0.3 ±0.30 .1 ±0.2 0.075 0.3 ±0.20 .2 ±0.1 0.028
22:6ω-3 (DHA) 13.6 ±2.61 2 .2 ±3.5n s 1 5 .1 ±6.11 4 .1 ±5.8n s
ω-6/ω-3 ratio 0.8 ±0.21 .1 ±0.4 0.015 0.8 ±0.51 .2 ±0.8 0.028
PI
Σω-6∗ 46.1 ±1.74 5 .7 ±1.8n s 4 5 .2 ±0.84 6 .6 ±1.0 0.046
18:2ω-6 (LA) 3.9 ±0.84 .1 ±0.8n s 3 .0 ±1.83 .7 ±1.7n s
20:4ω-6 (AA)∗∗ 34.1 ±2.33 2 .6 ±2.3 0.066 33.0 ±3.43 4 .0 ±3.6 0.028
Σω-3 1.6 ±0.51 .5 ±1.0n s 2 .2 ±1.11 .7 ±0.9n s
18:3ω-3 (ALA) <0.01 <0.01 <0.01 <0.01
20:5ω-3 (EPA) 0.09 ±0.09 0.02 ±0.03 0.042 0.08 ±0.07 0.03 ±0.04 0.0686 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 2: Continued.
Female (n = 12)
P value
Male (n = 7)
P value
ω-3 Control ω-3 Control
22:6ω-3 (DHA) 0.7 ±0.30 .8 ±0.8n s 0 .9 ±0.90 .8 ±0.6n s
ω-6/ω-3 ratio 31.1 ±9.14 7 .5 ±35.5 0.086 26.4 ±14.33 4 .3 ±18.4 ns
DPG
Σω-6 92.0 ±4.99 0 .4 ±2.2n s 8 9 .9 ±3.29 1 .9 ±2.0n s
18:2ω-6 (LA) 90.8 ±4.98 9 .0 ±2.1n s 8 7 .5 ±3.78 9 .9 ±2.4 0.028
20:4ω-6 (AA) 0.7 ±0.40 .5 ±1.0n s 1 .7 ±0.71 .3 ±0.5n s
Σω-3 1.1 ±0.41 .1 ±1.0n s 1 .7 ±0.51 .2 ±0.4 0.063
18:3ω-3 (ALA) 0.6 ±0.20 .5 ±0.2n s 0 .5 ±0.10 .6 ±0.1 0.091
20:5ω-3 (EPA) 0.13 ±0.18 0.05 ±0.07 0.075 0.34 ±0.16 0.12 ±0.08 0.028
22:6ω-3 (DHA) 0.2 ±0.20 .5 ±1.0n s 0 .5 ±0.30 .2 ±0.3 0.046
ω-6/ω-3 ratio 94.2 ±35.5 120.4 ±85.8n s5 6 .6 ±19.48 1 .7 ±20.0 0.063
Data are presented as means ± SD. P values of paired Wilcoxon signed-ranks test of the values after n-3 and placebo treatment. ∗P<0.05, ∗∗P<0.01,
comparing males and females by delta values.
omega-3 fatty acids, play a role in the insulin and glucose
metabolism in obese girls at this young age. The diﬀerences
induced by the omega-3 LCPUFA supplementation were
often slightly higher in the females, reﬂected in a higher
signiﬁcance level, which might indicate that boys might need
a longer or more intensive supplementation. The diﬀerence
in results might also be related to the lower number of boys
in the study.
Glucose tolerance and peripheral insulin sensitivity are
mostly regulated by the FA composition in the liver and
skeletal muscle [7, 23]. It has been shown that obese children
with impaired glucose tolerance demonstrate defects in
nonoxidative glucosemetabolism, andintramyocellular lipid
accumulation is related to insulin resistance [13]. A number
of diﬀerent metabolic abnormalities may increase intramy-
ocellular FA metabolites, such as increased fat delivery to
muscle as a consequence of either excess energy intake, liver
disturbances, or defects in adipocyte fat metabolism [24].
Another possible mechanism behind intramyocellular lipid
accumulation would be reduced mitochondrial oxidative
phosphorylation,sincemitochondriawithinthecellsconvert
FA and glucose into energy via beta-oxidation. Indeed,
mitochondrial dysfunction causes deposits of lipids inside
the muscle, producing insulin resistance and leading to
diabetes [25]. It is possible that the improved glucose and
insulinmetabolismafteromega-3LCPUFAsupplementation
can be attributed to decreased muscle triacylglycerides. We
found that omega-3 LCPUFA supplementation led to a non-
signiﬁcant decrease in the level of muscle triacylglycerides
(34% in girls and 15% in boys), which might support such
hypothesis. Decreased insulin sensitivity has been shown
to be associated with decreased total percentage of C20–
22PUFAs in skeletal muscle phospholipids [15]. In our
studies, the omega-3 LCPUFA supplementation increased
total percentage of C20–22PUFAs of the omega-3 series in
skeletal muscle phospholipids. Since mitochondria are rich
in DHA, it was of interest that in phosphatidylethanolamine
and phosphatidylserine, especially concentrated in the inner
membrane of the mitochondria [26], there were signiﬁcant
changes in the ratios between long chain omega-6 and
omega-3 fatty acids. In phosphatidylethanolamine, there
were large changes in the concentration of EPA, DHA, and
AA. Our data in obese girls are intriguing inasmuch as the
changes in the FA composition of muscles may contribute
to the improved glucose and insulin metabolism. A large
study completed with analyses of membrane receptors and
transcription factors involved in glucose/insulin metabolism
would be of interest.
A decrease in visceral fat would also be associated with
increased insulin sensitivity [13], but during this relatively
short time of the study anthropometry did not change. A
long-term study would be of interest, in the context that
Huber and co-workers found that a high-fat diet induced
adipose tissue remodelling in obese diabetic mice was pre-
vented by supplementation with omega-3 LCPUFA [27].
The omega-3 LCPUFA supplementation improved glu-
cose and insulin metabolism only in the females in spite of
favourable changes in skeletal muscle phospholipid FA in
both sexes. There were fewer boys, but factors other than
changes in muscle FA may be involved in the improved glu-
cose and insulin metabolism induced by omega-3 LCPUFA
supplementation. Gender diﬀerences in omega-3 PUFA me-
tabolism have been reported (for review, see [28]). Women,
but not men, responded to a high oleate/low palmitate
diet by markedly increased FA oxidation [29]. Interestingly,
Phang demonstrated that gender diﬀerences existed in
plateletaggregationinresponsetovariousomega-3LCPUFA
supplements [30]. It might be possible that dietary FA,
such as omega-3 LCPUFAs, and sex hormones (particularly
oestrogen) can act synergistically to improve glucose and in-
sulin metabolism in female obese adolescents. This warrants
further investigations.
There is evidence that the impaired insulin sensitivity in
obese girls starts even before puberty. In a study of healthy
4-year olds, we found that in girls, but not in boys, serum
fasting insulin concentration and HOMA-IR were associated
with the weight gain from birth to 4 years, and higher
weight was found in those with low omega-3 FA intakeJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
0 2 04 06 08 0 1 0 0
Time (min)
0
5
10
15
20
25
30
Female
G
l
u
c
o
s
e
(
m
M
)
∗
∗
∗
∗
∗
(a)
02 0 4 0 6 0 8 0 1 0 0
Time (min)
0
5
10
15
20
25
30
G
l
u
c
o
s
e
(
m
M
)
Male
(b)
0 2 04 06 08 0
Time (min)
0
50
100
150
200
250
I
n
s
u
l
i
n
(
m
U
/
L
)
∗∗
∗∗ ∗ ∗
Omega 3
Placebo
100
(c)
0
50
100
150
200
250
I
n
s
u
l
i
n
(
m
U
/
L
)
−50
02 0 4 0 6 0 8 0 1 0 0
Time (min)
Omega 3
Placebo
(d)
Omega 3 Placebo
−0.05
−0.04
−0.03
−0.02
−0.01
0
G
l
u
c
o
s
e
 
d
i
s
a
p
p
e
a
r
a
n
c
e
 
c
o
n
s
t
a
n
t
 
(
K
g
)
∗
(e)
Omega 3 Placebo
−0.05
−0.04
−0.03
−0.02
−0.01
0
G
l
u
c
o
s
e
 
d
i
s
a
p
p
e
a
r
a
n
c
e
 
c
o
n
s
t
a
n
t
 
(
K
g
)
(f)
Figure 1: Intravenous glucose tolerance test: glucose (upper panels) and insulin (middle panels) response curves after omega-3 LCPUFA or
placebo supplementation, in male (right panels) and female (left panels) obese adolescents. Omega-3 LCPUFA supplementation increased
glucose disappearance rate (lower panels) and improved restoration of insulin concentration in female, but not male subjects.
∗P<0.05, ∗∗P<0.01 compared with placebo.8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
[31]. Fatty acid composition of food intake, that is, high
intake of omega-6PUFAs, early in life is also related to the
development of insulin resistance and obesity in children
[32]. High weight gain and symptoms of the metabolic
syndrome in adult rats, which only in the perinatal period
were given a ratio of essential fatty acids of omega-6/omega-
3 of 9:1, commonly found in human diets, indicated that
programming by FA might occur perinatally resulting in
diseases later in life [33]. Insulin resistance was found in rats
with n-3 FA deﬁciency [34], and we have shown earlier that
obese children had lower concentrations of omega-3 fatty
acids in serum phospholipidsv [4], which may contribute to
the development of insulin resistance.
Major limitations of our study are the small number of
subjects and the short time of intervention. Notwithstanding
these restraints, we showed that 3 months of intervention
with omega-3 LCPUFAs in a high physiological dose was
suﬃcient to improve glucose and insulin metabolism in
obese girls, as well as the FA pattern in the skeletal muscle
in both gender. Our results are in agreement with a recently
published study in obese mice [35]. High doses, such as
4g/day used in other studies [36], would probably give
stronger eﬀects, but are also less physiological considering
thatthesubjectsdidnothavediabetes.Clinicalinvestigations
of obese children and adolescents approaching basic physi-
ological eﬀects might provide a more “pure situation” with
little inﬂuence of other confounding risk factors and would
thus be valuable to extend.
In conclusion, after a relatively short intervention period
with 1.2g/day of omega-3 LCPUFA supplementation, the
fatty acid composition of skeletal muscle phospholipids and
muscle triacylglycerols improved in both obese boys and
girls. Improved glucose and insulin metabolism in the obese
girls indicated a speciﬁc eﬀect since anthropometry did not
change. Girls have previously been found to be at higher risk
of developing insulin resistance [16], an abnormality that
mightstillbereversibleatthisearlyage.Long-termstudiesin
larger group of children would be most important to verify
these preliminary results.
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